Compare AbbVie Inc (ABBV) vs TKO Group Holdings Inc (TKO) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

TKO trades at $186.56, down 0.39% on the day, with a bullish technical signal and strong analyst support. The company reported record Q2 2026 revenue of $1.55 billion (up 18% year-over-year) and raised full-year guidance, though it missed EPS estimates. Valuation ratios are elevated with a P/E of 66.46, but profitability metrics show improvement. Recent corporate actions include an $800 million share repurchase and a $0.79 dividend payment.

The outlook is positive driven by media rights growth and live events, with a consensus price target of $228.17 implying 22% upside. Risks include earnings volatility and institutional selling. Wall Street sentiment remains strongly bullish with 89% buy ratings.